The New Immunosuppressant Efficient to Inhibit the Chronic Rejection?
Authors:
O. Viklický; I. Matl
Authors‘ workplace:
Klinika nefrologie, Transplantcentrum, Institut klinické a experimentální medicíny, Praha
Published in:
Čas. Lék. čes. 2001; : 22-25
Category:
Overview
Chronic rejection represents the most common cause of transplanted graft loss in the long term. Rapamycin(sirolimus), and it’s derivate RAD, are new and potent, immunosuppressive drugs. They inhibit cell proliferationdriven by various growth factors. These drugs were successfully tested in some experimental models of the chronicrejection. Results of the first clinical trials have defined rapamycin pharmacokinetics and proved immunosuppressiveefficacy. Rapamycin acts synergistically with cyclosporin A. The side effects are a dose-dependent thrombocytopeniaand leukopenia but the most frequent is hyperlipidemia. The question, if rapamycin and RAD inhibit developmentof chronic rejection in man, will be solved by the prospective clinical trials over years.
Key words:
rapamycin, chronic rejection.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- The New Immunosuppressant Efficient to Inhibit the Chronic Rejection?
- The Cori Husband and Wife, Prague-Born Nobel Laureates
- Social Determinants of Health in the European Context. Basic Facts and Recommendationsfor Practice in the Healthy-Cities Context
- Peroxisomes – Features, Biogenesis and Regulation of the Peroxisome Genes